122 related articles for article (PubMed ID: 25489685)
1. [Imatinib for pulmonary arterial hypertension].
Hoeper MM; Opitz C; Olschewski H; Ulrich S; Speich R; Behr J; Halank M; Wilkens H; Klose H; Lange TJ; Grünig E; Seeger W; Ewert R; Borst MM; Welte T; Rosenkranz S; Ghofrani HA
Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S151-4. PubMed ID: 25489685
[No Abstract] [Full Text] [Related]
2. Ventricular interdependence in pulmonary arterial hypertension: providing small pieces of a complex puzzle.
Gorter TM; Willems TP; van Melle JP
Eur J Heart Fail; 2015 Jan; 17(1):1-2. PubMed ID: 25597868
[No Abstract] [Full Text] [Related]
3. The role of imatinib in the treatment of pulmonary hypertension.
Mucke H
Drugs Today (Barc); 2013 Mar; 49(3):203-11. PubMed ID: 23527324
[TBL] [Abstract][Full Text] [Related]
4. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension.
ten Freyhaus H; Dumitrescu D; Bovenschulte H; Erdmann E; Rosenkranz S
Clin Res Cardiol; 2009 Apr; 98(4):265-7. PubMed ID: 19219392
[No Abstract] [Full Text] [Related]
5. [Chronic myelogenous leukemia: management of treatment-related adverse events].
Takahashi N
Rinsho Ketsueki; 2012 Oct; 53(10):1581-8. PubMed ID: 23037730
[No Abstract] [Full Text] [Related]
6. Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension.
Querejeta Roca G; Campbell P; Claggett B; Vazir A; Quinn D; Solomon SD; Shah AM
Eur J Heart Fail; 2015 Jan; 17(1):63-73. PubMed ID: 25367310
[TBL] [Abstract][Full Text] [Related]
7. Facial hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor.
Hamza I; Gaies E; Kastalli S; Daghfous R; El Aidli S
Therapie; 2014; 69(3):245-7. PubMed ID: 24934821
[TBL] [Abstract][Full Text] [Related]
8. Imatinib in neurofibromatosis type 2.
Lim S; de Souza P
BMJ Case Rep; 2013 Jul; 2013():. PubMed ID: 23839611
[TBL] [Abstract][Full Text] [Related]
9. [Chronic myeloid Leukemia - clinical practice according to the JSH guideline for hematological malignancies].
Yahagi Y
Gan To Kagaku Ryoho; 2014 May; 41(5):567-71. PubMed ID: 24956628
[No Abstract] [Full Text] [Related]
10. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Thielen N; van der Holt B; Verhoef GE; Ammerlaan RA; Sonneveld P; Janssen JJ; Deenik W; Falkenburg JH; Kersten MJ; Sinnige HA; Schipperus M; Schattenberg A; van Marwijk Kooy R; Smit WM; Chu IW; Valk PJ; Ossenkoppele GJ; Cornelissen JJ
Ann Hematol; 2013 Aug; 92(8):1049-56. PubMed ID: 23572137
[TBL] [Abstract][Full Text] [Related]
11. Recurrence of severe pulmonary hypertension following the removal of a lung allograft.
Grinnan DC; Fairman P; Pinson J
Chest; 2007 Dec; 132(6):2057-8; author reply 2058. PubMed ID: 18079249
[No Abstract] [Full Text] [Related]
12. Incidence of spontaneous subdural hematoma in incident cases of pulmonary arterial hypertension: a registry of cases occurring over a five-year period.
Prada LF; Gavilanes F; Souza R
J Bras Pneumol; 2015; 41(1):101-2. PubMed ID: 25750681
[No Abstract] [Full Text] [Related]
13. Imatinib mesylate for the treatment of pulmonary arterial hypertension.
ten Freyhaus H; Dumitrescu D; Berghausen E; Vantler M; Caglayan E; Rosenkranz S
Expert Opin Investig Drugs; 2012 Jan; 21(1):119-34. PubMed ID: 22074410
[TBL] [Abstract][Full Text] [Related]
14. [Treatment with imatinib for refractory PAH].
Nakamura K; Akagi S; Sarashina T; Ogawa A; Matsubara H; Ito H
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):173-7. PubMed ID: 24717604
[No Abstract] [Full Text] [Related]
15. Clinical research in pulmonary hypertension comes of age.
Barberà JA
Arch Bronconeumol; 2014 Nov; 50(11):463-4. PubMed ID: 24998025
[No Abstract] [Full Text] [Related]
16. Pulmonary toxicities of tyrosine kinase inhibitors.
Peerzada MM; Spiro TP; Daw HA
Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib.
Bournia VK; Evangelou K; Sfikakis PP
Semin Arthritis Rheum; 2013 Feb; 42(4):377-90. PubMed ID: 22789835
[TBL] [Abstract][Full Text] [Related]
18. Imatinib as rescue therapy in a patient with pulmonary hypertension associated with Gaucher disease.
Al-Naamani N; Roberts KE; Hill NS; Preston IR
Chest; 2014 Sep; 146(3):e81-e83. PubMed ID: 25180747
[TBL] [Abstract][Full Text] [Related]
19. Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.
Riva G; Luppi M; Lagreca I; Barozzi P; Quadrelli C; Vallerini D; Zanetti E; Basso S; Forghieri F; Morselli M; Maccaferri M; Paolini A; Fantuzzi V; Messerotti A; Maffei R; Iacobucci I; Martinelli G; Marasca R; Narni F; Comoli P; Potenza L
Br J Haematol; 2014 Jan; 164(2):299-302. PubMed ID: 24134676
[No Abstract] [Full Text] [Related]
20. Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?
Mendoza FA; Jiménez SA
Arthritis Rheum; 2011 Nov; 63(11):3199-203. PubMed ID: 21769846
[No Abstract] [Full Text] [Related]
[Next] [New Search]